Ermanin

Ermanin

SCHEMBL2875089

COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2OC)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 1.00
CYP2D6 P10635 3/20 1.00
KDM4E B2RXH2 2/20 0.85
POLB P06746 2/20 0.85
APEX1 P27695 2/20 0.85
RECQL P46063 2/20 0.85
POLH Q9Y253 2/20 0.85
MCL1 Q07820 1/20 0.85
ABCB1 P08183 4/20 0.79
MAOA P21397 3/20 0.79
CYP1A1 P04798 2/20 0.79
CYP1A2 P05177 2/20 0.79
CYP1B1 Q16678 2/20 0.79
FTO Q9C0B1 1/20 0.79
MAPT P10636 3/20 0.77
MEN1 O00255 2/20 0.77
KMT2A Q03164 2/20 0.77
MMP1 P03956 1/20 0.77
GAA P10253 1/20 0.77
HTT P42858 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4649968 0.94 CYP3A4 (0.88) CYP3A4CYP2D6KDM4EPOLBAPEX1
SCHEMBL30131217 0.94 CYP3A4 (0.88) CYP3A4CYP2D6KDM4EPOLBAPEX1
Isokaempferide SCHEMBL29721227 0.92 POLH (1.00) CYP3A4CYP2D6KDM4EPOLBAPEX1
Isokaempferide SCHEMBL1628023 0.92 POLH (1.00) CYP3A4CYP2D6KDM4EPOLBAPEX1
SCHEMBL31548920 0.89 CYP3A4 (0.80) CYP3A4CYP2D6KDM4EPOLBAPEX1
SCHEMBL3188065 0.89 POLH (0.83) CYP3A4CYP2D6KDM4EPOLBAPEX1
SCHEMBL11096105 0.89 POLH (0.83) CYP3A4CYP2D6KDM4EPOLBAPEX1
SCHEMBL20100899 0.89 CYP3A4 (0.80) CYP3A4CYP2D6KDM4EPOLBAPEX1
SCHEMBL15361036 0.89 POLH (0.83) CYP3A4CYP2D6KDM4EPOLBAPEX1
SCHEMBL4631662 0.88 ABCB1 (1.00) CYP3A4CYP2D6KDM4EPOLBAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
US-20220281903-A1 FLAVONOID DERIVATIVE FOR TREATING DENTAL CARIES MÜHLBAUER TECHNOLOGY GMBH (DE) 2022-09-08 US claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
EP-4017585-A1 FLAVONOID DERIVATIVE FOR TREATING DENTAL CARIES Mühlbauer Technology GmbH (DE) 2022-06-29 EP claimed
CN-113768921-A Application of methoxy flavonoid compound in preparing anti-leucoderma medicament 张波 2021-12-10 CN claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021032844-A1 FLAVONOID DERIVATIVE FOR TREATING DENTAL CARIES MÜHLBAUER TECHNOLOGY GMBH (DE) 2021-02-25 WO claimed
US-20040057908-A1 Oral compositions and use thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2004-03-25 US claimed
EP-1399119-A2 ORAL COMPOSITIONS AND USE THEREOF University of Rochester (US) 2004-03-24 EP claimed
WO-2002047615-A2 ORAL COMPOSITIONS AND USE THEREOF UNIVERSITY OF ROCHESTER (US) 2002-06-20 WO claimed
EP-0290442-A4 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. CHEMEX PHARMACEUTICALS INC (US) 1990-07-03 EP claimed
EP-0290442-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-11-17 EP claimed
US-4774229-A ANTITUMOR AGENTS, SKIN DISORDERS, CANCER TREATMENT CHEMEX PHARMACEUTICALS, INC. (US) 1988-09-27 US claimed
WO-1988003805-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-06-02 WO claimed
WO-1987006833-A1 MODIFICATION OF PLANT EXTRACTS FROM ZYGOPHYLLACEAE CHEMEX PHARMACEUTICALS, INC. (US) 1987-11-19 WO claimed
US-4352792-A 3-Alkoxyflavone antiviral agents HOFFMANN-LA ROCHE INC. (US) 1982-10-05 US claimed
EP-0019081-A1 Flavone derivatives, their preparation, these novel and known flavones as antiviral agents, and pharmaceutical compositions containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1980-11-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281903-A1 FLAVONOID DERIVATIVE FOR TREATING DENTAL CARIES ITGA8, ITGAL, ITGB2 CYP3A4 1785/4885CYP2D6 1816/4885KDM4E 192/4885
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB CYP3A4 3571/4885CYP2D6 4172/4885KDM4E 4637/4885
US-20040057908-A1 Oral compositions and use thereof UGGT1, DPM1, B4GALT1 CYP3A4 269/4885CYP2D6 419/4885KDM4E 3655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.